Teligent Inc. (TLGT) and Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) Comparing side by side

We are comparing Teligent Inc. (NASDAQ:TLGT) and Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) on their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Teligent Inc. 70.90M 1.06 27.99M -0.38 0.00
Merrimack Pharmaceuticals Inc. N/A 0.00 60.77M -2.98 0.00

In table 1 we can see Teligent Inc. and Merrimack Pharmaceuticals Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 represents Teligent Inc. (NASDAQ:TLGT) and Merrimack Pharmaceuticals Inc. (NASDAQ:MACK)’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Teligent Inc. -39.48% -70.2% -15%
Merrimack Pharmaceuticals Inc. 0.00% -58.4% -44.6%

Risk & Volatility

Teligent Inc. has a 1.59 beta, while its volatility is 59.00%, thus making it more volatile than Standard & Poor’s 500. Merrimack Pharmaceuticals Inc. on the other hand, has 2.57 beta which makes it 157.00% more volatile compared to Standard & Poor’s 500.

Dividends

The dividend yield for Merrimack Pharmaceuticals Inc. is 156.3% while its annual dividend payout is $10.55 per share. Teligent Inc. does not offer a dividend.

Analyst Ratings

Ratings and Recommendations for Teligent Inc. and Merrimack Pharmaceuticals Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Teligent Inc. 0 0 0 0.00
Merrimack Pharmaceuticals Inc. 0 1 0 2.00

Competitively Merrimack Pharmaceuticals Inc. has an average target price of $4, with potential downside of -44.75%.

Institutional and Insider Ownership

Teligent Inc. and Merrimack Pharmaceuticals Inc. has shares held by institutional investors as follows: 83.4% and 55.8%. About 0.3% of Teligent Inc.’s share are held by insiders. Competitively, 4.05% are Merrimack Pharmaceuticals Inc.’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Teligent Inc. 0% -9.41% -26.67% -61.01% -43.17% 12.41%
Merrimack Pharmaceuticals Inc. -2.42% 8.83% 36.65% 3.6% -44.49% 56.48%

For the past year Teligent Inc. has weaker performance than Merrimack Pharmaceuticals Inc.

Summary

Merrimack Pharmaceuticals Inc. beats Teligent Inc. on 6 of the 11 factors.

Teligent, Inc., a specialty generic pharmaceutical company, develops, formulates, manufactures, and markets generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. It also develops, manufactures, fills, and packages topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets. The companyÂ’s products are used in various applications that range from cosmetics and cosmeceuticals to the prescription treatment of conditions, such as dermatitis, psoriasis, and eczema. In addition, it offers contract formulation and contract manufacturing services comprising formulating, testing, and/or manufacturing prescription drugs and medical devices. The company was formerly known as IGI Laboratories, Inc. and changed its name to Teligent, Inc. in October 2015. Teligent, Inc. was founded in 1977 and is based in Buena, New Jersey.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company's therapeutic oncology candidates in clinical development include MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer; and MM-141 that is in Phase II clinical trial for treating previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1. Its therapeutic oncology candidates also comprise MM-310 for treating solid tumors; and MM-151 that has completed a Phase I clinical trial for treating solid tumors. Further, it is developing preclinical product candidates for solid tumor indications. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.